About RP Bio
RP Bio is a publicly listed company based in Seoul (South Korea) founded in 1983. Semisolid drugs are manufactured by RP Bio as a CDMO. The company has 493 employees. Its chief executive, as recorded, is Jae H Yoon. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation.
Company details
RP Bio was established in 1983 in Seoul, South Korea, and operates within the pharmaceutical sector as a contract development and manufacturing organization. Focus is placed on the production of semisolid drug formulations, with services encompassing development and manufacturing processes. Operations are centered in South Korea, supporting clients in the biopharmaceutical industry through specialized expertise in semisolid dosage forms.
- Headquarters Seoul, South Korea
- Employees 493
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website rpskorea.com
- Legal Name Rpbio Inc.
- Annual Revenue$94.32 M (USD)9.88as on Dec 31, 2025
- Net Profit$3.24 M (USD)as on Dec 31, 2025
- EBITDA$7.96 M (USD)87.7as on Dec 31, 2025
- Employee Count493
People of RP Bio
1 people are tracked at RP Bio (1 in leadership); the tracked headcount is 493.
| Name | Role | Group |
|---|---|---|
Jae H Yoon | CEO | Leadership |
Complete people profiles for RP Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of RP Bio
RP Bio is a publicly listed company on the KRX with ticker symbol 314140 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Sep 2022
- Listed onKRX: 314140
- Listed entityRPbio Inc.
- Exchange sectorHealth technology
- ISINKR7314140005
- Share price5,500.00 KRW (+0.18% on the day) · 2026-10-14
- Market capitalisation47,487,634,020.00 KRW
- Price to earnings7.1
- EPS (diluted, trailing year)777.56 KRW
- Dividend yield0.88%
- Volume (last session)7,507
Financials of RP Bio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 136.22B KRW | 4.68B KRW | 11.50B KRW |
| 2024 | 123.97B KRW | -907.1M KRW | 6.12B KRW |
| 2023 | 151.05B KRW | 5.44B KRW | 12.67B KRW |
| 2022 | 138.11B KRW | 4.32B KRW | 15.05B KRW |
| 2021 | 114.96B KRW | 3.81B KRW |
Detailed financial statements for RP Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of RP Bio
Websites that share an audience with RP Bio (rpskorea.com).
Websites whose visitors overlap most with RP Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| whosaeng.com | 100% | 150.5K | #310,255 | View details | |
| pharmnews.com | 100% | #274,610 | View details | ||
| ahn-gook.com | 73% | 25.7K | #653,877 | View details | |
rpbio.co.kr | rpbio.co.kr | 32% | #3,654,419 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about RP Bio
RP Bio was founded in 1983.
RP Bio is headquartered in Seoul, South Korea.
Jae H Yoon is the CEO of RP Bio, as recorded in our data.
RP Bio has 493 employees.
Annual revenue of RP Bio is $94.32M as on Dec 31, 2025.
RP Bio was established in 1983 in Seoul, South Korea, and operates within the pharmaceutical sector as a contract development and manufacturing organization. Focus is placed on the production of semisolid drug formulations, with services encompassing development and manufacturing processes. Operations are centered in South Korea, supporting clients in the biopharmaceutical industry through specialized expertise in semisolid dosage forms.
Yes, RP Bio is publicly traded on KRX under the ticker symbol 314140.